GENSCRIPT BIO

GenScript Biotech retreated 1.2% to HK$17.20, a pullback reflecting both recent earnings headwinds and profit-taking momentum. The company's Q4 2025 operating revenue surged 42.75% year-over-year to HK$1.71 billion, yet net losses deepened to -HK$1.97 billion with diluted EPS of -HK$0.91, underscoring the typical cash burn of early-stage biotech ventures. The brighter spot remains the CAR-T therapy CARVYKTI—developed through partnership with Legend Biotech—which has shown strong commercial momentum and encouraging clinical efficacy in blood cancer treatment, recently driving a 7% block-trade rally. However, management subsequently issued investor caution signals. Year-to-date the stock is up 34.48% from HK$12.79, now trading well above both 20-day and 60-day moving averages, though still 11% below the 52-week high of HK$19.40, illustrating investors' continuing tug-of-war between therapeutic promise and financial distress.

GenScript Biotech started the morning session at HK$16.51 and rallied to a session high of HK$17.29 at 10:12 a.m., representing a 2.4% gain, but retreated in afternoon trading to close at HK$16.81, roughly flat versus the prior close of HK$16.82. The morning's strength was primarily driven by positive momentum stemming from affiliate Legend Biotech's CAR-T pipeline progress, particularly CARVYKTI's robust sales momentum and LB2501's encouraging clinical efficacy data in relapsed/refractory B-cell lymphoma, though profit-taking at higher levels limited sustained afternoon gains. On the earnings front, Q3/Q4 operating revenue expanded 42.7% year-over-year, but net profit remained negative due to elevated R&D investments. Valuation-wise, the stock is up 31.43% year-to-date but trades 13.35% below its 52-week high of HK$19.4, currently trading above the MA60 in a resilient uptrend.

GenScript Biotech rose to 16.83 HKD in morning trading (up 4.6%), supported by block trade activity, but subsequently retreated as investors took profits, closing at 16.10 HKD with minimal change. The recent momentum reflects strong commercial performance of CARVYKTI, a CAR-T cell therapy from Legend Biotech, an associate company treating blood cancers. Q4 2025 revenue reached 1.714 billion HKD, expanding 42.75% year-over-year, showing robust business growth, yet the company reported a net loss of 1.974 billion HKD, typical of early-stage biotech firms with substantial R&D spending. Regarding valuation, the stock has gained 25.88% year-to-date, trading 17% below its 52-week high of 19.4 HKD while maintaining a premium above its 60-day moving average of 13.37 HKD. While revenue growth remains strong, the company's ongoing losses warrant continued monitoring.

GenScript Biotech rose 3% today, primarily driven by positive clinical progress of CAR-T therapy LB2501 from affiliate Legend Biotech. The stock surged to 16.20 in the morning session and extended gains into the afternoon, reaching an intraday high of 16.44, reflecting optimistic market sentiment toward the clinical pipeline. Latest quarterly results show operating revenue grew 42.7% year-over-year to HK$1.715B, demonstrating strong business expansion momentum, while net loss remained at HK$1.974B with a negative net margin of -115%, typical of biotech companies in heavy investment phase. On valuation, the stock has gained 25.8% year-to-date with a market cap of HK$35.2B, but still trades 17% below the 52-week high of HK$19.40. Notably, today's turnover rate of 0.95% was relatively modest, suggesting limited institutional participation; further gains would require stronger catalysts.

GenScript Biotech surged around 7% today on a block trade, reaching an intraday high of HK$16.62 and closing at HK$15.62. The rally is underpinned by positive clinical data from associated company Legend Biotech's CAR-T therapy LB2501, which provides medium-term support to earnings outlook. Yet recent financials reveal a deep tension: Q4 2025 revenue surged 42.75% year-over-year to HK$1.71 billion and operating income swung positive, but net loss ballooned to HK$1.97 billion with a -115% net margin, underscoring the company's heavy research-funding burn phase. From a valuation standpoint, GenScript has gained 22.13% year-to-date and sits 19.48% below its 52-week high of HK$19.4, with the current price of HK$15.62 trading above both the 20-day moving average (HK$13.52) and 60-day moving average (HK$13.29), suggesting a near-term recovery posture, though questions linger about the cash-burn model's sustainability.